Community Trust Bancorp Inc
Change company Symbol lookup
Select an option...
CTBI Community Trust Bancorp Inc
$NYLGCAPT NYSE U.S. Large Cap Equal Weight Ind
VIVC Vivic Corp
BAC Bank of America Corp
DGRW WisdomTree U.S. Quality Dividend Growth Fund
DFP Flaherty & Crumrine Dynamic Preferred and Income Fund
DFP Flaherty & Crumrine Dynamic Preferred and Income Fund
DES WisdomTree U.S. SmallCap Dividend Fund
DEO Diageo PLC
DDF Delaware Investments Dividend and Income Fund
Go

Financials : Banks | Small Cap Blend
Company profile

Community Trust Bancorp, Inc. is a bank holding company. The Company holds interests in a commercial bank, Community Trust Bank, Inc. (the Bank), and a trust company, Community Trust and Investment Company. Through its subsidiaries, the Company engages in a range of commercial and personal banking, and trust and wealth management activities, which include accepting time and demand deposits; making secured and unsecured loans to corporations, individuals and others; providing cash management services to corporate and individual customers; issuing letters of credit; renting safe deposit boxes, and providing funds transfer services. Its loan portfolio includes commercial loans, such as construction loans, loans secured by real estate, equipment lease financing and commercial other loans; residential loans, such as real estate construction loans, real estate mortgages and home equity loans, and consumer loans, such as consumer direct loans and consumer indirect loans.

Closing Price
$31.57
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
63,569
0

Roche's shares rise on news of study testing Actemra, remdesivir in COVID-19 patients

7:34 am ET May 28, 2020 (MarketWatch)
Print

Shares of Roche Holding AG gained 2.4% in premarket trading on Thursday after the drugmaker said it is testing a combination of its rheumatoid arthritis drug Actemra with Gilead Sciences Inc.'s (GILD) remdesivir in hospitalized COVID-19 patients. Gilead's stock was down 0.4%. Roche has previously announced it is studying Actemra in 450 hospitalized COVID-19 patients participating in a randomized, double-blind, placebo-controlled late-stage trial; results from that trial are expected "this summer," Roche said. The new Phase 3, randomized, double-blind, multicenter study will test Actemra and remdesivir against placebo and remdesivir in about 450 patients hospitalized with severe COVID-19 pneumonia. Trial sites are in Canada, Europe, and the U.S. The Food and Drug Administration granted an emergency use authorization (http://www.marketwatch.com/story/how-gileads-remdesivir-became-the-leader-in-the-rush-to-find-a-treatment-for-covid-19-2020-05-01) to remdesivir on May 1 as a treatment for some severely ill COVID-19 patients. The experimental drug has not been approved as a treatment for the disease caused by the coronavirus. Since the start of the year, Roche's stock is up 8.2%, Gilead's stock has gained 15.2%, and the S&P 500 has declined 6.0%.

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

May 28, 2020 07:34 ET (11:34 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.